Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

Abstract: A rotary shaver for tissue resection includes an elongated outer tubular member, an elongated inner cutting member disposed in and operatively rotatable relative to the outer tubular member for cutting a tissue, and an elongated jaw member disposed in the outer tubular member to surround the inner cutting member and operatively turnable to cooperate with an outer distal portion of the outer tubular member so as to clamp and electrocauterize the tissue for creating hemostasis during a surgical procedure.

Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.

Abstract: The present invention is directed to anti-sense microRNA-328 in a form of oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The present invention is also directed to a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. The present invention is further directed to a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition. A preferred route of administration is topical administration to the eyes.

Abstract: The present disclosure discloses a ceramic material having a positive slow release effect and a method for manufacturing the same. The ceramic material comprises a hierarchically meso-macroporous structure which composition at least includes silicon and oxygen, wherein the hierarchically meso-macroporous structure includes a plurality of macropores and a wall having a plurality of arranged mesopores, and the plurality of macropores are separated by the wall; and nano-scale metal particles confined in at least one of the plurality of arranged mesopores. The nano-scale metal particles have a positive slow release effect from the at least one of the plurality of arranged mesopores. The ceramic material has a property of inhibiting growth of microorganisms or killing the microorganisms in an environment or a system containing a hydrophilic medium.

Abstract: A method of treating a subject suffering from an angiogenesis-related disease, which is implemented by administering to the subject a pharmaceutical composition comprising a compound of formula I derived from Mitella formosana to inhibit the angiogenic function of endothelial progenitor cells.

Abstract: An automatic cell isolation and collection system for sorting out target cells from a sample includes a crush module, a centrifuge module, a transport module, and a control unit. The centrifuge module includes centrifuge tubes and a magnetic mechanism providing a magnetically attractive force to at least one of the centrifuge tubes. The control unit electrically communicates with the crush module, the centrifuge module, and the transport module, and controls operation of the crush module, transport of the sample via the transport module after the sample is crushed by the crush module, centrifugation of the centrifuge module, and operation of the magnetic mechanism for providing the magnetically attractive force.

Abstract: The present invention provides a composition for isolating adipose-derived stromal cells, which comprises a Type I collagenase of 0.5-8% (v/v); a Trypsin of 0.1-0.6% (v/v); and a metal ion chelating agent of 0.01-0.2% (v/v). The present invention further provides a method for isolating adipose-derived stromal cells, which method comprises obtaining an adipose tissue; treating the adipose tissue with the composition of the present invention; centrifuging the adipose tissue; and isolating the adipose tissue to obtain the adipose-derived stromal cells. The present invention facilitates rapid isolation of mesenchymal stromal cells within a short period of time in operating rooms and can be applied to regenerative medicine in the future.

Abstract: Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4?-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR? inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR? ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1? (IL-1?) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

Abstract: An avatar-based charting method for assisted diagnosis to improve the efficiency of medical practice. Through an anthropomorphic symptom record interface, the first page is the Genetic-Psycho-Social-Bio (GPSB) which assists in understanding the genetic, psychological, social-environmental, and biological characteristics of patients. A Subjective-Objective-Assessment-Plan (SOAP) diagnosis page aids in doctor diagnosis. A decision support diagnostic summary interface automatically generates the diagnosis summary and notifies of any unusual circumstances. Finally, a medical records module saves all information into a medical database in order to provide health care for subsequent tracking and evaluation.

Abstract: The present invention provides a method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from chronic hepatitis C comprising: (a) measuring gene expression levels of genes comprising RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3 and DDX60 of a blood sample from the subject after one week of the peginterferon plus ribavirin treatment; and (b) calculating a gene score according to cumulative fold change of the gene expression levels, when the gene score is equal to or higher than a cut-off value, the method predicts successful treatment of chronic hepatitis C with the peginterferon plus ribavirin treatment for the subject.

Abstract: The invention provides an oligonucleotide comprising a nucleotide sequence consisting of SEQ ID NO: 1. The invention also provides method for detecting target DNA in a sample with the oligonucleotide.

Abstract: The present invention is directed to anti-sense microRNA-328 in a form of oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The present invention is also directed to a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. The present invention is further directed to a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition. A preferred route of administration is topical administration to the eyes.

Abstract: A composition for inhibiting a liver tumor in an organism is disclosed. The composition includes an activator being 1,2,3,4,6-penta-O-galloyl-Beta-D-glucopyranoside (PGG), wherein PGG is extracted from at least one of Paeonia lactiflora Pall. and Galla Chinesis.

Abstract: The present invention relates to a use of a pharmaceutical composition in the preparation of a drug for promoting chondrogenesis, wherein the pharmaceutical composition comprises a hyaluronic acid mixture and a statin compound.

Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.

Abstract: The present invention provides a method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from chronic hepatitis C comprising: (a) measuring gene expression levels of genes comprising RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3 and DDX60 of a blood sample from the subject after one week of the peginterferon plus ribavirin treatment; and (b) calculating a gene score according to cumulative fold change of the gene expression levels, when the gene score is equal to or higher than a cut-off value, the method predicts successful treatment of chronic hepatitis C with the peginterferon plus ribavirin treatment for the subject.

Abstract: The present invention relates to a non-invasive positioning system for screwing and fixing a bone, where a intramedullary nail is inserted to marrow of the bone, and the intramedullary nail comprises a wall and at least one through-hole through the wall for screwing and fixing by at least one corresponding set screw, the system comprises: an in vitro locator having at least one light source to emit a laser with a wavelength to the muscle tissue to form an incident light and running through the muscle tissue and the bone to form a penetrated light, an optical holder having an optical lens and a positioning ring portion for removably disposing the optical lens, wherein the focusing spot of the incident light, the focusing spot of the penetrated light, and the at least one through-hole are aligned in a line to confirm a linear position for screwing and fixing the intramedullary nail.

Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.